Day One Biopharmaceuticals, Inc. (DAWN)Healthcare | Biotechnology | Brisbane, United States | NasdaqGS
21.48 USD
+0.01
(0.047%)
⇧
(April 20, 2026, 4 p.m.
EDT)
Short-term: ★★★★☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 1:41 a.m. EDT
DAWN is a classic high-risk, high-reward 'merger story' trade. The stock has rallied 300%+ on the $2.5B Servier acquisition, trading at the exact 52-week high of $21.47. While the short-term technicals are bullish with coin contracts and 52-week highs providing a magnetic ceiling, the fundamentals remain broken: negative earnings, negative free cash flow, and a P/E that is undefined (forward earnings are also negative, though improving). As the price approaches $21.49, a sell-off toward the $17-20 range (50-day/200-day averages) is probable. Investable only for a speculative 'momentum kicker' prior to the merger close, not as a core holding. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.334022 |
| AutoARIMA | 0.335577 |
| AutoETS | 0.335577 |
| AutoTheta | 0.335961 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 29.10 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.031 |
| Excess Kurtosis | -1.89 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.633 |
| Revenue per Share | 1.533 |
| Market Cap | 2,219,617,792 |
| Forward P/E | -502.93 |
| Beta | -1.75 |
| Profit Margins | -67.85% |
| Website | https://dayonebio.com |
As of April 19, 2026, 1:41 a.m. EDT: Options flow shows a distinct divergence in sentiment by expiration. Near-term April (expiring in 10 days) exhibits asymmetric positioning with massive call volume/interest (12 vol, 2.2k OI at 22 strike) compared to negligible put volume (389 vol, 15.1k OI), yet the Open Interest ratio heavily favors calls (OTM OI% 0.16 vs 0 for April Puts implies heavy call accumulation despite the high put volume metric which may reflect older positioning or specific large block trades). The price is trading near 52-week highs ($21.45), pricing in a major merger thesis. Mid-term (May/July) flows show heavy put volume (e.g., 150+ at $15 strike) against flat open interest, suggesting traders are using calls for exposure to the upside while hedging or betting on volatility, or potentially selling straddles given the high implied volatility (0.55 vs 0.06 for July). Essentially, speculators are positioning for upside momentum via near-term calls but maintaining defensive hedges via further-dated puts.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.930423 |
| Address1 | 1,800 Sierra Point Parkway |
| Address2 | Suite 200 |
| All Time High | 28.699 |
| All Time Low | 5.44 |
| Ask | 27.5 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 3.0 - Hold |
| Average Daily Volume10 Day | 1,415,330 |
| Average Daily Volume3 Month | 4,011,091 |
| Average Volume | 4,011,091 |
| Average Volume10Days | 1,415,330 |
| Beta | -1.748 |
| Bid | 15.47 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 4.284 |
| City | Brisbane |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 21.48 |
| Current Ratio | 8.015 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 21.49 |
| Day Low | 21.48 |
| Debt To Equity | 0.633 |
| Display Name | Day One Biopharmaceuticals |
| Earnings Call Timestamp End | 1,771,968,600 |
| Earnings Call Timestamp Start | 1,771,968,600 |
| Earnings Timestamp | 1,771,966,800 |
| Earnings Timestamp End | 1,778,011,200 |
| Earnings Timestamp Start | 1,778,011,200 |
| Ebitda | -124,274,000 |
| Ebitda Margins | -0.78564 |
| Enterprise To Ebitda | -14.327 |
| Enterprise To Revenue | 11.256 |
| Enterprise Value | 1,780,514,432 |
| Eps Current Year | -0.75506 |
| Eps Forward | -0.04271 |
| Eps Trailing Twelve Months | -1.04 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 17.6116 |
| Fifty Day Average Change | 3.8683987 |
| Fifty Day Average Change Percent | 0.2196506 |
| Fifty Two Week Change Percent | 193.0423 |
| Fifty Two Week High | 21.49 |
| Fifty Two Week High Change | -0.010000229 |
| Fifty Two Week High Change Percent | -0.00046534336 |
| Fifty Two Week Low | 5.635 |
| Fifty Two Week Low Change | 15.844999 |
| Fifty Two Week Low Change Percent | 2.8118896 |
| Fifty Two Week Range | 5.635 - 21.49 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,622,122,200,000 |
| Float Shares | 70,727,929 |
| Forward Eps | -0.04271 |
| Forward P E | -502.92673 |
| Free Cashflow | -61,958,752 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 178 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.8912 |
| Gross Profits | 140,972,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.16861 |
| Held Percent Institutions | 0.85462 |
| Implied Shares Outstanding | 103,334,169 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-05-27 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Day One Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral and brain-penetrant type II rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It is also developing DAY301, a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody conjugated with a topoisomerase I inhibitor via a highly stable and hydrophilic modified valine-alanine (VA) cleavable linker for the treatment of patients with advanced solid tumors; and Emi-Le, an antibody-drug conjugate that targets B7- H4 conjugated to an auristatin anti-tubulin payload as a component of a proprietary linker-payload platform developed by Mersana Therapeutics that is in Phase 1 clinicla trial for the treatment of breast cancer, ovarian cancer, endometrial cancer, and adenoid cystic carcinoma (ACC). Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California. |
| Long Name | Day One Biopharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 2,219,617,792 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_704589075 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -107,322,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,220,651,291 |
| Number Of Analyst Opinions | 6 |
| Open | 21.49 |
| Operating Cashflow | -103,757,000 |
| Operating Margins | -0.51115 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 650 484 0899 |
| Pre Market Change | 0.010000229 |
| Pre Market Change Percent | 0.046556 |
| Pre Market Price | 21.49 |
| Pre Market Time | 1,776,766,668 |
| Previous Close | 21.47 |
| Price Eps Current Year | -28.448069 |
| Price Hint | 2 |
| Price To Book | 5.0140057 |
| Price To Sales Trailing12 Months | 14.03205 |
| Profit Margins | -0.67847 |
| Quick Ratio | 7.73 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 3.0 |
| Region | US |
| Regular Market Change | 0.01 |
| Regular Market Change Percent | 0.046578 |
| Regular Market Day High | 21.49 |
| Regular Market Day Low | 21.48 |
| Regular Market Day Range | 21.48 - 21.49 |
| Regular Market Open | 21.49 |
| Regular Market Previous Close | 21.47 |
| Regular Market Price | 21.48 |
| Regular Market Time | 1,776,715,201 |
| Regular Market Volume | 1,561,479 |
| Return On Assets | -0.14642 |
| Return On Equity | -0.2274 |
| Revenue Growth | 0.839 |
| Revenue Per Share | 1.533 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 103,334,169 |
| Shares Percent Shares Out | 0.0701 |
| Shares Short | 7,236,832 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 10,152,747 |
| Short Name | Day One Biopharmaceuticals, Inc |
| Short Percent Of Float | 0.1033 |
| Short Ratio | 0.92 |
| Source Interval | 15 |
| State | CA |
| Symbol | DAWN |
| Target High Price | 21.5 |
| Target Low Price | 21.5 |
| Target Mean Price | 21.5 |
| Target Median Price | 21.5 |
| Total Cash | 441,112,992 |
| Total Cash Per Share | 4.27 |
| Total Debt | 2,793,000 |
| Total Revenue | 158,182,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.04 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 10.501075 |
| Two Hundred Day Average Change | 10.978925 |
| Two Hundred Day Average Change Percent | 1.0455048 |
| Type Disp | Equity |
| Volume | 1,561,479 |
| Website | https://dayonebio.com |
| Zip | 94,005 |